Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunologic diseases, complement-mediated diseases, and addictive disorders. The company has no ongoing product revenue from continuing operations and relies on royalty income from its former product, OMIDRIA (reported as discontinued operations), and capital raises to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Net Loss (Continuing Operations) | $(63.5) million | $(109.0) million |
| Net Loss (Total) | $(58.9) million | $(93.2) million |
| Net Income from Discontinued Operations | $4.6 million | $15.8 million |
| Research & Development Expenses | $45.9 million | $72.1 million |
| Selling, General & Administrative Expenses | $21.5 million | $26.1 million |
| Cash Used in Operating Activities | $(57.8) million | $(87.8) million |
| Cash, Cash Equivalents & Short-Term Investments | $28.7 million | $90.1 million (Dec 31, 2024) |
| Total Debt (Carrying Value) | $167.8 million | $187.6 million (Dec 31, 2024) |
Note: Revenue from continuing operations is $0. The company reported no product sales in the current period.
Material Changes vs. Prior Period
- Debt Restructuring: In May 2025, the company exchanged $70.8 million of its 2026 Convertible Senior Notes for new 2029 Notes and converted $10.0 million of 2026 Notes into common stock (Equitization Transaction). This reduced the 2026 Notes principal balance from $97.9 million to $17.1 million.
- Interest Expense Reduction: Total interest expense decreased significantly to $3.7 million for the six months ended June 30, 2025, compared to $17.4 million in the prior year. This was primarily driven by a $11.9 million non-cash remeasurement gain on the OMIDRIA royalty obligation and reduced principal on the 2026 Notes.
- R&D Spend Reduction: R&D expenses decreased by $26.3 million year-over-year, largely due to reduced manufacturing costs for zaltenibart, the termination of the narsoplimab Phase 3 program for IgA nephropathy, and the absence of prior-year drug substance batch release costs.
- Discontinued Operations: Net income from discontinued operations (OMIDRIA) dropped to $4.6 million from $15.8 million, attributed to a remeasurement adjustment reflecting lower forecasted OMIDRIA sales.
Guidance, Outlook, and Risks
Regulatory Milestones
- Narsoplimab (TA-TMA): The FDA PDUFA decision date for the resubmitted Biologics License Application (BLA) was extended to December 26, 2025. Labeling discussions are planned to begin no later than October 2025.
- European Approval: A Marketing Authorization Application (MAA) for narsoplimab was submitted to the EMA in June 2025, with an expected opinion in mid-2026.
Capital Resources and Liquidity
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for one year from the filing date due to the need for additional capital to cover operating costs.
- Recent Financing: On July 28, 2025 (post-period), the company completed a registered direct offering, raising approximately $20.6 million net proceeds.
- ATM Facility: The company has an At-The-Market (ATM) facility with up to $150.0 million capacity. It raised $6.4 million during the six months ended June 30, 2025, and an additional $2.1 million subsequently.
- Covenants: The company must maintain at least $25.0 million in unrestricted cash, cash equivalents, and short-term investments. As of June 30, 2025, the balance was $28.7 million, satisfying the covenant.
Operational Adjustments
- Paused Programs: Due to capital constraints, the company has temporarily paused its Phase 3 clinical development program for zaltenibart in PNH and reduced activities in the OMS1029 and MASP-2 small-molecule programs.
- Strategic Discussions: The company is in discussions regarding potential asset acquisition or licensing agreements, with one potential transaction valued in the multi-billions that could repay the Term Loan and 2026 Notes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $28.7 million cash balance plus the $20.6 million post-period raise against the $57.8 million operating cash burn rate for the first half of the year.
- Debt Covenants: Monitor the $25.0 million minimum liquidity covenant under the Credit Agreement, especially given the high burn rate.
- Regulatory Timeline: Track the FDA review progress for narsoplimab leading up to the December 26, 2025, PDUFA date.
- Equitization Settlement: Confirm the final settlement of the $10.0 million Note Conversion Agreement (Equitization Transaction) scheduled for completion by September 15, 2025.
- Strategic Transactions: Assess the likelihood and terms of the discussed asset licensing/acquisition deals intended to resolve liquidity constraints.